Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gemcitabine
Drug ID BADD_D01009
Description Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers.[A233135] Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose.[A233145] As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells.[L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.[A233140] Gemcitabine is marketed as Gemzar and it is available as intravenous injection. It is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [cisplatin], and pancreatic cancer as monotherapy.[L32950] It is also being investigated in other cancer and tumour types.
Indications and Usage Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
Marketing Status Prescription; Discontinued
ATC Code L01BC05
DrugBank ID DB00441
KEGG ID D02368
MeSH ID C056507
PubChem ID 60750
TTD Drug ID D03UVS
NDC Product Code 0409-0182; 0409-0185; 65129-1235; 16729-419; 0409-0181; 63323-102; 55111-687; 62756-008; 63323-125; 62756-321; 0143-9395; 16729-426; 62756-073; 68001-342; 16729-391; 63323-126; 68001-350; 16729-423; 0409-0187; 62756-219; 62756-533; 62756-974; 68001-348; 68001-359; 62756-438; 62756-102; 0409-0186; 55111-686; 0409-0183; 62756-614; 0143-9394; 62756-746
Synonyms gemcitabine | 2',2'-difluoro-2'-deoxycytidine | gemicitabine | 2'-deoxy-2'-difluorocytidine | dFdCyd | 2',2'-DFDC | 2',2'-difluorodeoxycytidine | gemcitabine hydrochloride | LY 188011 | LY-188011 | gemcitabine, (beta-D-threo-pentafuranosyl)-isomer | gemcitabine, (D-threo-pentafuranosyl)-isomer | Gemzar | 2'-deoxy-2',2''-difluorocytidine-5'-O-monophosphate | gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Chemical Information
Molecular Formula C9H11F2N3O4
CAS Registry Number 95058-81-4
SMILES C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
FatigueEpidermal growth factor receptorP00533T5932826362459
FatigueReceptor tyrosine-protein kinase erbB-2P04626T1459726362459
Neoplasm related morbiditiesTumor necrosis factor receptor superfamily member 10BO14763T7006714716031; 15364135; 14977831; 14668933
Neoplasm related morbiditiesApoptosis regulator Bcl-2P10415T3130914716031; 15364135; 14977831; 14668933
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Generalised oedema14.05.06.007; 08.01.07.0040.003996%
Glomerulonephritis20.05.01.001; 10.02.01.0060.000533%Not Available
Gravitational oedema08.01.07.005; 02.05.04.0140.001332%Not Available
Haemangioma16.02.01.002; 24.03.06.0040.000533%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.001332%Not Available
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin decreased13.01.05.0030.007992%Not Available
Haemolysis01.06.04.0020.000799%
Haemolytic anaemia01.06.03.0020.002664%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.029838%
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhoids24.10.02.002; 07.15.03.0010.000533%
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hemiparesis17.01.04.001--
Hepatic atrophy09.01.08.0040.000799%Not Available
Hepatic cirrhosis09.01.04.0010.000208%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.001332%Not Available
Hepatic failure09.01.03.0020.000973%
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.0020.000208%
Hepatic steatosis09.01.07.003; 14.08.04.0050.001066%Not Available
Hepatitis09.01.07.0040.001865%Not Available
Hepatitis acute09.01.07.0050.000533%Not Available
Hepatitis B11.05.06.002; 09.01.09.0030.001598%
Hepatitis cholestatic09.01.01.0020.000799%Not Available
Hepatocellular injury09.01.07.0080.006394%Not Available
Hepatorenal syndrome20.01.03.012; 09.01.03.0070.000139%Not Available
Hepatotoxicity09.01.07.009; 12.03.01.0080.001332%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 21 Pages